Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Completed 12Recruiting 11Active not recruiting 10Terminated 7Unknown 6Not yet recruiting 6Withdrawn 1No longer available 1Enrolling by invitation 1

Sponsor Class

OTHER 5OTHER_GOV 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Thoracic 4Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 2Lung Neoplasms 2Meningeal Carcinomatosis 1Lymphoma, Large-Cell, Anaplastic 1Brain Neoplasms 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Unknown × lorlatinib × Clear all
NCT06410040 2024-05-10

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Sichuan Cancer Hospital and Research Institute

Unknown
28 enrolled
CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT03505554 2023-08-07

CRU3

University of Milano Bicocca

Phase 2 Unknown
12 enrolled
Lymphoid

Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

National Cancer Center, Korea

Phase 2 Unknown
35 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03439215 2021-07-19

PFROST

Fondazione Ricerca Traslazionale

Phase 2 Unknown
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown
96 enrolled
Thoracic

Lung Neoplasms, Recurrence

NCT02927340 2021-03-09

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Massachusetts General Hospital

Phase 2 Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡